Examine the Phase III Clinical Data Recently Released About ACAPODENE in the Treatment of Prostate Cancer
Posted on: Friday, 25 April 2008, 09:01 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c90005) has announced the addition of "Market Potential of ACAPODENE® FOR ADT-Associated Osteoporosis: A Panel Discussion among Nine Physicians Specializing in the Treatment of Prostate Cancer" to their offering.
Deliverable: Transcript with key findings.
Study Objectives:
To conduct a panel discussion among urologists who specialize in the treatment of prostate cancer to examine the phase III clinical data recently released about ACAPODENE® (toremifene citrate) and evaluate how this drug might influence clinical practice if it were to receive FDA approval.
- Understand current prevention and treatment practices regarding androgen deprivation therapy (ADT)-associated osteoporosis.
- Examine the phase III trial results for ACAPODENE®
- - Discuss the study design.
- - Explore any concerns about the study.
- Evaluate the potential clinical benefits of the drug -- are the study results clinically meaningful?
- Explore the potential use of ACAPODENE® and identify which patients might receive the medication.
- Assess how the drug might be used relative to other medications to prevent and treat ADT-associated osteoporosis.
- Gauge opinion about the safety of ACAPODENE®, particularly related to the risk of venous thromboembolic events (VTE).
- Elucidate whether panelists would utilize a 60mg generic version of ACAPODENE®.
- Uncover any other important issues surrounding ACAPODENE® and the phase III trial results.
Inclusion Criteria:
- US-based
- Training and board-certified in specialty
- 2 - 30 years of experience post-training
- From academic medical centers and community hospitals
- Treats patients for osteoporosis associated with ADT given for prostate cancer
- Must not have participated in the phase III trial being discussed or other trials for GTx, Inc.
- Request disclosure of past and current consulting relationships
- Must not have current or past professional relationship with GTx, Inc.
Institutions represented:
- Urologic Oncology Practice, University of California San Francisco
- Dana-Farber Cancer Institute
- Hematology/Oncology Associates at the University Hospital in Newark
- Columbia University Medical Center
- Urology Associates of Norwalk
- Private Practice
- Albany Urology Clinic
- Indiana University
- Central Bucks Urology
Companies mentioned:
- GTx
- Novartis
- Merck
- Amgen
For more information visit http://www.researchandmarkets.com/reports/c90005.
Source: Business Wire
Related Articles
- Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
- ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
- Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), Which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
- Medarex Reports Interim Data From Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
- Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
- Medicure Announces Special Protocol Assessment With the FDA For Phase III MEND-CABG II Study
- EntreMed Commences Panzem(R) NCD Phase 2 Study in Prostate Cancer
- Dendreon Announces Publication of Pivotal Phase 3 Study Highlighting Survival Benefit and Safety Profile of PROVENGE in Men With Advanced Prostate Cancer
- Threshold Pharmaceuticals Completes Enrollment in a Phase 2 Study for the Treatment of Benign Prostatic Hyperplasia
- ChemGenex to Initiate Phase II Study With Quinamed in Prostate Cancer; Anti-Cancer Activity Observed in Recently Completed Phase I Study
 |
 |
User Comments (0)
RSS Feeds